Highlights Newsletter 1
This newsletter presents you the following key sessions:
3. Patient-reported outcomes from the CodeBreaK 200 trial favour sotorasib over docetaxel
4. Addition of eftilagimod alpha to pembrolizumab may revert resistance to anti-PD-1/PD-L1 therapy